Solutions for diagnostic and therapeutic follow-up
With more than 250.000 doses injected in France every year, FluoroDeoxyGlucose (FDG) enables an initial diagnostic of many cancers and to adjust more than 40% of patients’ therapy. As a complement to FDG, there is an increasing need for more specific molecules. That’s why we invest more than 10% of our revenues in R&D.
Tous droits réservés, Cyclopharma 2014